These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19153780)

  • 1. Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses.
    Cichero E; Cesarini S; Spallarossa A; Mosti L; Fossa P
    J Mol Model; 2009 Jul; 15(7):871-84. PubMed ID: 19153780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
    Cichero E; Cesarini S; Fossa P; Spallarossa A; Mosti L
    Eur J Med Chem; 2009 May; 44(5):2059-70. PubMed ID: 19046616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Cichero E; Fossa P
    J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
    Cichero E; Buffa L; Fossa P
    J Mol Model; 2011 Jul; 17(7):1537-50. PubMed ID: 20922443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Schenone S; Bruno O; Bondavalli F; Vargiu L; Marceddu T; Mura M; La Colla P; Pani A
    J Med Chem; 2003 Feb; 46(5):768-81. PubMed ID: 12593657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Sivan SK; Manga V
    J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Spallarossa A; Cesarini S; Ranise A; Schenone S; Bruno O; Borassi A; La Colla P; Pezzullo M; Sanna G; Collu G; Secci B; Loddo R
    Eur J Med Chem; 2009 May; 44(5):2190-201. PubMed ID: 19058881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
    Mao Y; Li Y; Hao M; Zhang S; Ai C
    J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Cichero E; Cesarini S; Spallarossa A; Mosti L; Fossa P
    J Mol Model; 2009 Apr; 15(4):357-67. PubMed ID: 19066996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Hu R; Barbault F; Delamar M; Zhang R
    Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
    Xu HR; Fu L; Zhan P; Liu XY
    SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties.
    Zhang Y; Chen L; Wang Z; Zhu Y; Jiang H; Xu J; Xiong F
    J Biomol Struct Dyn; 2024 May; 42(8):4196-4213. PubMed ID: 37272892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
    J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
    Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
    Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
    Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
    Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
    J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.